eISSN: 2081-2841
ISSN: 1689-832X
Journal of Contemporary Brachytherapy
Current Issue Archive Supplements Articles in Press Journal Information Aims and Scope Editorial Office Editorial Board Register as Author Register as Reviewer Instructions for Authors Abstracting and indexing Subscription Advertising Information Links
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
6/2020
vol. 12
 
Share:
Send email
Share:
abstract:
Original paper

Ten-year longitudinal health-related quality of life following iodine-125 brachytherapy monotherapy for localized prostate cancer

Finbar Slevin
1
,
Brinda Sethugavalar
1
,
Bashar Al-Qaisieh
2
,
Peter Bownes
2
,
Joshua Mason
2
,
Jonathan Smith
3
,
David Bottomley
1
,
Ann M Henry
1

  1. Department of Clinical Oncology, Leeds Teaching Hospital NHS Trust, Leeds, UK
  2. Department of Medical Physics, Leeds Teaching Hospital NHS Trust, Leeds, UK
  3. Department of Clinical Radiology, Leeds Teaching Hospital NHS Trust, Leeds, UK
J Contemp Brachytherapy 2020; 12, 6: 540–546
DOI: https://doi.org/10.5114/jcb.2020.101686
Online publish date: 2020/12/18
View full text Get citation
 
Purpose
This prospective longitudinal study quantifies health-related quality of life (HRQoL) up to 10 years following permanent iodine-125 (125I) prostate brachytherapy alone for localized prostate cancer.

Material and methods
In total, 120 patients completed a validated expanded prostate cancer index composite (EPIC) questionnaire pre-treatment and at 8 time points after treatment (6 weeks, 6, 10, 18 months, and 2, 3, 5, 10 years). At each time point, clinically relevant small, moderate, and severe declines in HRQoL were defined as 0.2-0.5 SD, 0.5-0.8 SD, and > 0.8 SD of baseline function for each of urinary, bowel, and sexual domains, respectively.

Results
Response rates in the first two years were > 90%, but thereafter dropped to 75% and 48% at 5 and 10 years, respectively. 50 patients (41.6%) responded at all stages. Maximal deterioration in mean urinary and sexual summary scores was noted 6 weeks after implant, with severe urinary symptoms and moderate bowel/sexual symptoms. At 6 months, urinary and bowel quality of life (QoL) had improved to mild impairment, which then fully resolved at 10 months. Sexual QoL remained mildly impaired throughout the 10 years of follow-up. At 10 years, new mild impairment of urinary and bowel QoL was found.

Conclusions
Clinically mild changes in urinary, bowel, and sexual QoL are found 10 years after 125I monotherapy. The impairment in sexual function persists from treatment, but urinary and bowel symptoms are new at 10 years.

keywords:

brachytherapy, iodine-125, quality of life, prostate cancer

  
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.